Medical Science Liaison (MSL) - Southwest

About the role

The Medical Science Liaison (MSL) is responsible for the identification and engagement of a targeted group of national and regional thought leaders/healthcare professionals (HCPs), as well as payers and managed care accounts. This position provides consistent delivery of educational and compliant scientific information in support of Karyopharm’s pipeline.

This is a uniquely exciting time to join Karyopharm Therapeutics where we are pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. We are building upon an established commercial foundation in multiple myeloma while advancing the potential of selinexor across additional hematologic and solid tumor cancers including myelofibrosis and TP53 wild-type endometrial cancer, areas where patients continue to face significant unmet needs. Our lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1) and is approved in the U.S. for adults with relapsed or refractory multiple myeloma, with approvals in more than 50 countries and territories outside the U.S. We are also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms and TP53 wild-type driven solid tumors using next-generation compounds, including eltanexor. As we prepare for our next phase of growth, we are continuing to invest in critical capabilities across the organization to support future opportunities and deepen our impact in oncology. We are looking for talented people who are motivated by meaningful work, energized by growth and momentum, and excited by the opportunity to help shape what comes next in a collaborative, fast-moving environment where individual contributions are visible and valued. Learn more at Karyopharm Therapeutics.

Responsibilities

• Identify and develop relationships with community/academic thought leaders along with treatment advocates on a local, regional, and national level.
• Serve as Karyopharm’s scientific representative to the medical community and facilitate the appropriate exchange of scientific information.
• Provide clinical and economic value information to payers and formulary